Monte Rosa Financials
| GLUE Stock | USD 9.11 0.51 5.93% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.5 | 5.0698 |
|
|
The financial analysis of Monte Rosa is a critical element in measuring its lifeblood. Investors should not minimize Monte Rosa's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Monte | Select Account or Indicator |
Understanding current and past Monte Rosa Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Monte Rosa's financial statements are interrelated, with each one affecting the others. For example, an increase in Monte Rosa's assets may result in an increase in income on the income statement.
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.
Monte Rosa Stock Summary
Monte Rosa competes with Bright Minds, HP, Intel, Chevron Corp, and Coca Cola. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. Monte Rosa operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 93 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US61225M1027 |
| CUSIP | 61225M102 |
| Location | Massachusetts; U.S.A |
| Business Address | 321 Harrison Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.monterosatx.com |
| Phone | 617 949 2643 |
| Currency | USD - US Dollar |
Monte Rosa Key Financial Ratios
| Return On Equity | -0.61 | ||||
| Operating Margin | (2.88) % | ||||
| Price To Sales | 35.28 X | ||||
| EBITDA | (137.09 M) | ||||
| Net Income | (135.35 M) |
Monte Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Monte Rosa's current stock value. Our valuation model uses many indicators to compare Monte Rosa value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Monte Rosa competition to find correlations between indicators driving Monte Rosa's intrinsic value. More Info.Monte Rosa Therapeutics is one of the top stocks in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . At present, Monte Rosa's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Monte Rosa by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Monte Rosa Therapeutics Systematic Risk
Monte Rosa's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Monte Rosa volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Monte Rosa Therapeutics correlated with the market. If Beta is less than 0 Monte Rosa generally moves in the opposite direction as compared to the market. If Monte Rosa Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Monte Rosa Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Monte Rosa is generally in the same direction as the market. If Beta > 1 Monte Rosa moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Monte Rosa Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Monte Rosa's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Monte Rosa growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Monte Rosa November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Monte Rosa help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Monte Rosa Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Monte Rosa Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Monte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Monte Rosa's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.53 | |||
| Information Ratio | 0.0565 | |||
| Maximum Drawdown | 102.66 | |||
| Value At Risk | (8.18) | |||
| Potential Upside | 7.42 |
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |